Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
 

Learn about the flu shot, COVID-19 vaccine, and our masking policy »

Stanford Health Care

NICOTINIC-CATECHOLAMINERGIC INTERACTIONS IN RAT-BRAIN - EVIDENCE FOR CHOLINERGIC NICOTINIC AND MUSCARINIC INTERACTIONS WITH HYPOTHALAMIC EPINEPHRINE JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS Roth, K. A., McIntire, S. L., BARCHAS, J. D. 1982; 221 (2): 416-420

Abstract

The i.p. injection of nicotine produced several changes in regional catecholamine concentrations in rat brain. These changes were blocked by the centrally active nicotinic antagonist mecamylamine, but not by the quaternary nicotinic antagonist hexamethonium. An examination of the effects of various cholinergic agents on hypothalamic epinephrine concentrations revealed several interesting findings. Central muscarinic antagonism or peripheral muscarinic agonism decreased hypothalamic epinephrine concentrations. The anticholinesterase physostigmine decreased hypothalamic epinephrine concentrations and this effect was blocked by the centrally acting nicotinic antagonist mecamylamine, but not by hexamethonium, scopolamine or methscopolamine. These findings indicate an interaction of cholinergic receptors, both nicotinic and muscarinic, with hypothalamic epinephrine.

View details for Web of Science ID A1982NQ08000024

View details for PubMedID 7077536